Jagsonpal Pharmaceuticals Q2 Results FY27: PAT Flat at Rs 12.59 Cr, Revenue Rs 81.38 Cr
- October 28, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Jagsonpal Pharmaceuticals Q2 Results FY27 were declared on 28 October 2026 on a Standalone basis. Revenue rose 9.28% YoY to Rs 81.38 Cr from Rs 74.47 Cr, while net profit edged up 0.16% to Rs 12.59 Cr from Rs 12.57 Cr. Operating Profit stood at Rs 16.77 Cr in these quarterly results.
Jagsonpal Pharmaceuticals Ltd Q2 Results FY27 announced on 28 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought standalone revenue of Rs 81.38 Cr and net profit (PAT) of Rs 12.59 Cr. Jagsonpal Pharmaceuticals Q2 Results FY27 therefore pair a clear rise in sales with a nearly unchanged profit, and these standalone results frame the analysis below.
This results analysis of Jagsonpal Pharmaceuticals Q2 Results covers the financial highlights, business drivers, outlook and risks. It begins with the Financial Highlights table, assembled from the figures Univest tracks for each listed company as it reports.
Click Here – Get Free Investment Predictions
Jagsonpal Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 81.38 Cr | Rs 74.47 Cr | +9.28% YoY |
| Operating Profit | Rs 16.77 Cr | Rs 16.43 Cr | +2.07% YoY |
| Net Profit (PAT) | Rs 12.59 Cr | Rs 12.57 Cr | +0.16% YoY |
Source: company filing for Jagsonpal Pharmaceuticals Q2 Results FY27, 28 October 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Jagsonpal Pharmaceuticals Q2 Results: What Stands Out
- Revenue YoY growth of 9.28%: standalone revenue reached Rs 81.38 Cr against Rs 74.47 Cr in the same quarter of last year.
- Net profit up 0.16%: Jagsonpal Pharmaceuticals Q2 Results FY27 show net profit of Rs 12.59 Cr compared with Rs 12.57 Cr a year earlier, a gain of Rs 0.02 Cr.
- Operating Profit Rs 16.77 Cr: this line rose 2.07% YoY from Rs 16.43 Cr, a gain of Rs 0.34 Cr that trailed revenue growth.
- Margin squeeze: net profit margin narrowed to 15.5% from 16.9% in the comparison quarter, so profit stayed level as sales grew.
- Return ratios: return on equity was 18.19% and return on capital employed was 22.69% in FY26, both full-year figures.
Jagsonpal Pharmaceuticals Q2 Results FY27: Performance Analysis
Jagsonpal Pharmaceuticals Q2 Results FY27 show standalone revenue of Rs 81.38 Cr, up 9.28% from Rs 74.47 Cr, while net profit rose 0.16% to Rs 12.59 Cr from Rs 12.57 Cr. Operating Profit of Rs 16.77 Cr was 2.07% higher than the Rs 16.43 Cr recorded a year earlier. Sales therefore grew far faster than profit.
Within Jagsonpal Pharmaceuticals Q2 Results FY27, the size of each change is the central point of the results analysis. Revenue added Rs 6.91 Cr YoY, Operating Profit added Rs 0.34 Cr and net profit added Rs 0.02 Cr. A narrower net profit margin of 15.5%, against 16.9% a year earlier, links these moves in the standalone statement.
Investors tracking Jagsonpal Pharmaceuticals Q2 Results will also look at the sequential picture, since revenue was down 1.0% quarter on quarter from Rs 82.23 Cr and net profit was down 4.5% from Rs 13.19 Cr. The results analysis therefore records a YoY gain in sales alongside lower figures than the preceding quarter.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 9.3% year on year to Rs 81.38 Cr in the latest quarter. This is the disclosed top-line factor behind the standalone figures.
Profit Held Level – Net profit rose 0.2% year on year to Rs 12.59 Cr. This is a small gain, and it shows that most of the extra revenue did not reach the bottom line in the quarter.
Returns on Capital – Return on equity was 18.19% and return on capital employed was 22.69% in FY26. These full-year ratios describe how much profit the business earned on shareholder funds and on total capital before the latest quarter.
FY27 Outlook After Jagsonpal Pharmaceuticals Q2 Results
Full-year FY27 results for Jagsonpal Pharmaceuticals will turn on the quarters still to be reported, and the July to September 2026 period is one input. On a results analysis basis, Rs 12.59 Cr of net profit sets the comparison for the next filing.
Jagsonpal Pharmaceuticals Q2 Results FY27 leave two reference points for the rest of the year: revenue growth of 9.28% and a net profit gain of 0.16%. Investors can follow later disclosures on the Univest Screener and the Univest app, which brings the discussion to the risks.
Key Risks to Watch After Jagsonpal Pharmaceuticals Q2 Results FY27
Narrower Net Profit Margin
Net profit margin narrowed to 15.5% from 16.9% in the comparison quarter. Jagsonpal Pharmaceuticals Q2 Results FY27 show this squeeze alongside higher sales, so investors will watch whether later filings restore the earlier margin.
Lower Revenue Than the Previous Quarter
Revenue was down 1.0% quarter on quarter from Rs 82.23 Cr. This sequential dip sits beside the YoY gain, so the next filing will show which direction the top line takes.
Lower Net Profit Than the Previous Quarter
Net profit was down 4.5% quarter on quarter from Rs 13.19 Cr. This is a larger sequential move than the revenue dip, and later quarters will show whether profit stabilises.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Jagsonpal Pharmaceuticals Q2 Results FY27 show standalone revenue of Rs 81.38 Cr and net profit of Rs 12.59 Cr, which means higher sales but almost unchanged profit in the quarterly results. The moves are on record as standalone results in the filing dated 28 October 2026. Anyone reading Jagsonpal Pharmaceuticals Q2 Results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Jagsonpal Pharmaceuticals Q2 Results FY27
What are Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Jagsonpal Pharmaceuticals Q2 Results FY27 are the Standalone July to September 2026 results of Jagsonpal Pharmaceuticals, with revenue of Rs 81.38 Cr and net profit of Rs 12.59 Cr, as the Quick Answer summarises.
What is the results date for Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Jagsonpal Pharmaceuticals declared the quarter on 28 October 2026, so the results date covers the July to September 2026 period, while the introduction explains the standalone basis of the figures.
What revenue was reported in Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Jagsonpal Pharmaceuticals reported standalone revenue of Rs 81.38 Cr, against Rs 74.47 Cr a year earlier, so revenue added Rs 6.91 Cr, as the Financial Highlights table shows.
What net profit was reported in Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Jagsonpal Pharmaceuticals Q2 Results FY27 show net profit of Rs 12.59 Cr against Rs 12.57 Cr in the same quarter last year, so profit was almost flat, up by Rs 0.02 Cr, as the Key Takeaways section notes.
How much YoY growth did revenue show in Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Revenue grew 9.28% YoY in the July to September quarter, from Rs 74.47 Cr to Rs 81.38 Cr, while net profit rose only 0.16%, as the Performance Analysis explains.
Did net profit rise or fall in Jagsonpal Pharmaceuticals Q2 Results?
Ans. Jagsonpal Pharmaceuticals net profit rose 0.16% YoY to Rs 12.59 Cr from Rs 12.57 Cr, a very small gain beside the revenue growth, as the Performance Analysis section discusses.
What was the Operating Profit in Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. Operating Profit was Rs 16.77 Cr, up 2.07% from Rs 16.43 Cr a year earlier, so it grew more slowly than the 9.28% YoY revenue growth, as the Key Takeaways section outlines.
Are Jagsonpal Pharmaceuticals Q2 Results standalone results or consolidated results?
Ans. The figures are Standalone results, covering Jagsonpal Pharmaceuticals as a single company, so every revenue and profit number in the article follows the standalone basis stated in the introduction.
What business factors shaped Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. The disclosed factors are revenue growth of 9.3% YoY, a small rise in net profit, a return on equity of 18.19% in FY26, and a return on capital employed of 22.69% in FY26.
What are the key risks after Jagsonpal Pharmaceuticals Q2 Results FY27?
Ans. The listed risks are a narrower net profit margin of 15.5% against 16.9%, revenue down 1.0% from the previous quarter, and net profit down 4.5% from the previous quarter.
What is the outlook after Jagsonpal Pharmaceuticals Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, while Rs 12.59 Cr of quarterly net profit and 9.28% revenue growth are the reference points, as the Outlook section states.
Where can I find the complete Jagsonpal Pharmaceuticals Q2 Results FY27 data?
Ans. The Financial Highlights table in this article carries the full revenue and net profit comparison, while the Univest Screener lets investors follow Jagsonpal Pharmaceuticals filings alongside other listed companies.
